Balversa (erdafitinib) — United Healthcare
Pancreatic adenocarcinoma
Initial criteria
- Diagnosis of pancreatic adenocarcinoma
- Disease is one of the following: locally advanced OR metastatic OR recurrent
- Presence of FGFR genetic alterations
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Balversa therapy
Approval duration
12 months